重组人血管内皮抑素不同给药方式的研究进展  

Research Progress of Different Administration Routes of Recombinant Human Endostatin

作　　者：孙辰 田绍东 吴寒冰[2] 沙永红 SUN Chen;TIAN Shaodong;Wu Hanbing;SHA Yonghong(Jishou University School of Medicine,Jishou Hunan Province 416000;Huaihua First People's Hospital,Huaihua Hunan Province 418000)

机构地区：[1]吉首大学医学院,湖南吉首416000 [2]怀化市第一人民医院,湖南怀化418000 [3]怀化市第一人民医院肿瘤中心,湖南怀化418000

出　　处：《生命科学仪器》2022年第3期15-22,共8页Life Science Instruments

基　　金：怀化市科技计划项目应用基础研究项目,项目编号:2020yj011780

摘　　要：重组人血管内皮抑素(Endostar)-恩度,是我国自主研发的一种血管内皮抑制素。由于它传统的给药方式的给药时长、血药浓度波动大,患者们常常依从性较差且心脏细胞毒性具有较高反应。然而恩度的腔内灌注给药、瘤内直接注射以及微量泵持续泵入等新型给药方法有着更好的疗效和更高的安全性,这为拓宽血管内皮抑素的治疗适应症、提高患者的依从性、生活质量和疗效具有重要的临床意义。Recombinant human endostatin(Endostar)is a kind of vascular endostatin independently developed in our country.Due to it is traditional routes of administration,the length of administration and the large fluctuation of blood drug concentration,which patients often have poor compliance and high response to cardiac cytotoxicity,However,new administration routes of endostar have better efficacy and higher safety by intraluminal infusion,intratumoral direct injection and continuous pumping with micropump and so on.It is important clinical significance for broadening the therapeutic indications of endostatin and improving compliance and efficacy of patient.

关 键 词：重组人血管内皮抑素 给药方式 作用机制 持续静脉输入 

分 类 号：R730.5[医药卫生—肿瘤]